Bina Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bina Ahmed has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Faye Straight
4 shared publicationsHarold L. Dauerman
From the Division of Cardiology (B.A., H.L.D.), University of Vermont College of Medicine, Burlington, Vt; Section of Cardiology (W.D.P., D.M., J.R.), Dartmouth-Hitchcock Medical Center, Lebanon, NH; Division of Cardiology (P.V.), Eastern Maine Medical Center, Bangor, Me; Division of Cardiology (T.R.), Maine Medical Center, Portland, Me; Catholic Medical Center (M.H.), Manchester, NH; and Central Maine Medical Center (W.P.), Lewiston, Me
2 shared publications- Harold L. Dauerman
University of Vermont College of Medicine, Burlington, Vermont
2 shared publications Stefan Lischke
2 shared publicationsB. Delia Johnson
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
1 shared publication- Burton E. Sobel
Cardiovascular Research Institute and Department of Medicine, University of Vermont College of Medicine, Colchester, VT
1 shared publication
Latest Publications
- 1 August 2011
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 22 (5) , 311-316
Biomarker profiles as descriptors of left ventricular remodeling after acute myocardial infarction
Background Biomarker expression can predict subsequent cardiovascular events. The goal of this study was to determine the pattern of expression in blood of a broad array of cytokines and growth factors taken 24–72 h after an ST elevation myocardial infarction (STEMI) involving the left anterior descending (LAD) coronary artery. Methods Blood was taken from 16 patients with LAD STEMI. Cytokine and growth factor expressions were quantified with the use of a Milliplex cytokine/chemokine array analysis that tested 42 analytes. Results from patients were compared with those in blood from 20 healthy volunteers. Results Most (15/16) participants had positive remodeling without reduction in left ventricular function during follow-up. Analytes were grouped based on their function into those that activate class 1 T-helper cells (Th1 activates cell-mediated immunity), those that activated a Th2 response (activates humoral immunity and attenuates cell-mediated immunity), chemokines (attract leukocytes), and growth factors (promote a healing response). Elevation of cytokines involved in the Th2 response predominated over the Th1 response demonstrating a balance favoring tolerance and limiting activation of cell-mediated immunity. The concentration of selected chemokines favoring cell-mediated immunity was not elevated. The concentration of selected growth factors was increased. Conclusion The cytokine expression, 24–72 h after an LAD STEMI, suggests that positive ventricular remodeling is associated with growth factor expression and limitation of cell-mediated immunity. Subsequent studies are warranted to determine whether deviation from this pattern identifies patients at an increased risk of adverse remodeling after myocardial infarction.
- 1 August 2011
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 22 (5) , 311-316
Biomarker profiles as descriptors of left ventricular remodeling after acute myocardial infarction
Background Biomarker expression can predict subsequent cardiovascular events. The goal of this study was to determine the pattern of expression in blood of a broad array of cytokines and growth factors taken 24–72 h after an ST elevation myocardial infarction (STEMI) involving the left anterior descending (LAD) coronary artery. Methods Blood was taken from 16 patients with LAD STEMI. Cytokine and growth factor expressions were quantified with the use of a Milliplex cytokine/chemokine array analysis that tested 42 analytes. Results from patients were compared with those in blood from 20 healthy volunteers. Results Most (15/16) participants had positive remodeling without reduction in left ventricular function during follow-up. Analytes were grouped based on their function into those that activate class 1 T-helper cells (Th1 activates cell-mediated immunity), those that activated a Th2 response (activates humoral immunity and attenuates cell-mediated immunity), chemokines (attract leukocytes), and growth factors (promote a healing response). Elevation of cytokines involved in the Th2 response predominated over the Th1 response demonstrating a balance favoring tolerance and limiting activation of cell-mediated immunity. The concentration of selected chemokines favoring cell-mediated immunity was not elevated. The concentration of selected growth factors was increased. Conclusion The cytokine expression, 24–72 h after an LAD STEMI, suggests that positive ventricular remodeling is associated with growth factor expression and limitation of cell-mediated immunity. Subsequent studies are warranted to determine whether deviation from this pattern identifies patients at an increased risk of adverse remodeling after myocardial infarction.
- 1 November 2010
- Vol. 22 (11) , 512-6
Angiographic predictors of vascular complications among women undergoing cardiac catheterization and intervention.
Bleeding and vascular complications remain more common in women than men undergoing invasive cardiovascular procedures. We determined the role of femoral angiographic variables in risk-stratifying women for vascular complications. Between 2004-2009, all major bleeding and vascular complications among women undergoing diagnostic or interventional cardiovascular procedures were identified at a single center. Thirty consecutive female patients (major bleeding or vascular complication) were then age- and procedure-matched to 90 controls (no vascular complications). Quantitative femoral angiography was performed on all cases and controls. Smaller minimum luminal diameter was a strong univariate predictor of vascular complications in women (odds ratio [OR] 0.65; 95% confidence interval [CI] 0.47-0.90; p = 0.009), while site of arteriotomy was not predictive of complications. The prognostic significance of smaller femoral lumen diameter was mildly attenuated after adjusting for the predictive factor of smaller patient body size, even after adjusting for the predictive factor of smaller patient body size. Finally, multivariable modeling suggests that utilization of vascular closure devices (OR 0.26, 95% CI 0.07-0.96; p = 0.04) may be protective in women. Women with smaller femoral arteries are at significantly higher risk for bleeding and vascular complications than women with larger femoral arteries. Risk stratification for bleeding complications among women should account for clinical, pharmacologic and femoral angiographic factors.
- 1 November 2010
- Vol. 22 (11) , 512-6
Angiographic predictors of vascular complications among women undergoing cardiac catheterization and intervention.
Bleeding and vascular complications remain more common in women than men undergoing invasive cardiovascular procedures. We determined the role of femoral angiographic variables in risk-stratifying women for vascular complications. Between 2004-2009, all major bleeding and vascular complications among women undergoing diagnostic or interventional cardiovascular procedures were identified at a single center. Thirty consecutive female patients (major bleeding or vascular complication) were then age- and procedure-matched to 90 controls (no vascular complications). Quantitative femoral angiography was performed on all cases and controls. Smaller minimum luminal diameter was a strong univariate predictor of vascular complications in women (odds ratio [OR] 0.65; 95% confidence interval [CI] 0.47-0.90; p = 0.009), while site of arteriotomy was not predictive of complications. The prognostic significance of smaller femoral lumen diameter was mildly attenuated after adjusting for the predictive factor of smaller patient body size, even after adjusting for the predictive factor of smaller patient body size. Finally, multivariable modeling suggests that utilization of vascular closure devices (OR 0.26, 95% CI 0.07-0.96; p = 0.04) may be protective in women. Women with smaller femoral arteries are at significantly higher risk for bleeding and vascular complications than women with larger femoral arteries. Risk stratification for bleeding complications among women should account for clinical, pharmacologic and femoral angiographic factors.
- 1 October 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 2 (5) , 423-429
Significantly Improved Vascular Complications Among Women Undergoing Percutaneous Coronary Intervention
Women are at a higher risk for bleeding/vascular complications (VC) related to cardiovascular procedures. Although the overall incidence of percutaneous coronary intervention (PCI)-related bleeding/VC has declined, the impact of this decline, specifically in women, is unknown. We studied 13 653 female and 32 334 male consecutive cases, from 2002 to 2007, in the Northern New England PCI Registry. We sought to (1) compare absolute rates of bleeding/VC in women and men over time, (2) define predictors of bleeding/VC in women and men undergoing PCI, and (3) trend the impact of female gender in predicting bleeding/VC over time. Bleeding/VC was defined as any access-site vessel injury requiring surgical intervention or bleeding requiring transfusion. The overall risk of bleeding/VC was significantly higher in women versus men (4.5+/-1.3% versus 1.6+/-0.5%; P2-fold risk of bleeding/VC compared with men.
- 1 October 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 2 (5) , 423-429
Significantly Improved Vascular Complications Among Women Undergoing Percutaneous Coronary Intervention
Women are at a higher risk for bleeding/vascular complications (VC) related to cardiovascular procedures. Although the overall incidence of percutaneous coronary intervention (PCI)-related bleeding/VC has declined, the impact of this decline, specifically in women, is unknown. We studied 13 653 female and 32 334 male consecutive cases, from 2002 to 2007, in the Northern New England PCI Registry. We sought to (1) compare absolute rates of bleeding/VC in women and men over time, (2) define predictors of bleeding/VC in women and men undergoing PCI, and (3) trend the impact of female gender in predicting bleeding/VC over time. Bleeding/VC was defined as any access-site vessel injury requiring surgical intervention or bleeding requiring transfusion. The overall risk of bleeding/VC was significantly higher in women versus men (4.5+/-1.3% versus 1.6+/-0.5%; P2-fold risk of bleeding/VC compared with men.
- 1 September 2009
- Vol. 21 (9) , 429-33
Consistent door-to-balloon times of less than 90 minutes for STEMI patients transferred for primary PCI.
Recent data from large national registries show that < 15% of patients with ST-elevation myocardial infarction (STEMI) transferred for primary percutaneous intervention (PCI) actually meet the door-to-balloon (D2B) goal of < or = 90 minutes, and only onethird achieve D2B times of < or = 120 minutes. We established a streamlined STEMI protocol to allow rapid transfer of STEMI patients for primary PCI to meet the ACC D2B goal of < or = 90 minutes in at least 75% of the patients. From February 2007 to August 2008, 37 consecutive patients presenting with STEMI to a community hospital in Vermont were transferred 26 miles to the University of Vermont (UVM) for primary PCI. Three time intervals were evaluated: presentation to departure time at the referring hospital, transfer time and UVM PCI time (time from arrival to the cath lab to balloon time). Total D2B time was defined as presentation to the first hospital to first balloon inflation. The majority of transfers (69%) occurred off-hours. All patients received aspirin and clopidogrel and heparin pre-PCI. Median presentation to departure time at the STEMI referral hospital, total transfer and UVM PCI times were 26 (20, 33), 36 (34, 40) and 20 (16, 22) minutes, respectively. The median D2B time was 82 (77, 91) minutes, with 73% of patients achieving the goal D2B of < or = 90 minutes, and 94% achieving a D2B time of < or = 120 minutes. For patients in a rural setting who present with STEMI, transfer of approximately 30 miles for timely primary PCI can be achieved in nearly 75% of patients using a simplified streamlined protocol.
- 1 September 2009
- Vol. 21 (9) , 429-33
Consistent door-to-balloon times of less than 90 minutes for STEMI patients transferred for primary PCI.
Recent data from large national registries show that < 15% of patients with ST-elevation myocardial infarction (STEMI) transferred for primary percutaneous intervention (PCI) actually meet the door-to-balloon (D2B) goal of < or = 90 minutes, and only onethird achieve D2B times of < or = 120 minutes. We established a streamlined STEMI protocol to allow rapid transfer of STEMI patients for primary PCI to meet the ACC D2B goal of < or = 90 minutes in at least 75% of the patients. From February 2007 to August 2008, 37 consecutive patients presenting with STEMI to a community hospital in Vermont were transferred 26 miles to the University of Vermont (UVM) for primary PCI. Three time intervals were evaluated: presentation to departure time at the referring hospital, transfer time and UVM PCI time (time from arrival to the cath lab to balloon time). Total D2B time was defined as presentation to the first hospital to first balloon inflation. The majority of transfers (69%) occurred off-hours. All patients received aspirin and clopidogrel and heparin pre-PCI. Median presentation to departure time at the STEMI referral hospital, total transfer and UVM PCI times were 26 (20, 33), 36 (34, 40) and 20 (16, 22) minutes, respectively. The median D2B time was 82 (77, 91) minutes, with 73% of patients achieving the goal D2B of < or = 90 minutes, and 94% achieving a D2B time of < or = 120 minutes. For patients in a rural setting who present with STEMI, transfer of approximately 30 miles for timely primary PCI can be achieved in nearly 75% of patients using a simplified streamlined protocol.
- 11 July 2009
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 29 (3) , 282-288
Frequency and safety of switching antithrombin therapy at a regional PCI center
The impact of switching antithrombin therapy in patients presenting with acute coronary syndromes (ACS) and undergoing percutaneous intervention (PCI) has varied in clinical trials. We sought to assess the incidence and safety of switching antithrombin therapy in ACS patients undergoing PCI at a regional medical center. All patients with ACS undergoing PCI (n = 728) during a specified time period in 2005 and 2007 were identified. Patients who were switched to the antithrombin bivalirudin were defined as the “switch” group (n = 323) and all others were defined as the “consistent” therapy group (n = 405). Primary endpoints were major adverse cardiac event (MACE) (death, MI or urgent revascularization), major bleeding and net adverse clinical event (NACE) (MACE or major bleeding). Multivariate analysis was performed to determine if switching antithrombotic therapy predicted primary outcomes. Among 728 patients undergoing PCI for ACS, 44% were switched to bivalirudin. Switch patient were more likely to be transfers from outside hospitals, older, female, and diabetic. Angiographic characteristics were similar in the two groups. Switch patients had a similar incidence of MACE (7 vs. 8%, P = 0.72), major bleeding (2 vs. 2%) and NACE (9 vs. 10%, P = 0.51) when compared to those who received consistent therapy. On multivariate analysis, switching did not predict MACE (OR = 0.94, 95% CI = 0.53–1.67, P = 0.84) or NACE (OR = 0.82, 95%CI = 0.48–1.41, P = 0.47). In a regional clinical practice of patients presenting with ACS and undergoing PCI, switching of antithrombin therapy to bivalirudin is a common practice and patient who are switched have similar outcomes compared to patients who receive consistent therapy.
- 11 July 2009
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 29 (3) , 282-288
Frequency and safety of switching antithrombin therapy at a regional PCI center
The impact of switching antithrombin therapy in patients presenting with acute coronary syndromes (ACS) and undergoing percutaneous intervention (PCI) has varied in clinical trials. We sought to assess the incidence and safety of switching antithrombin therapy in ACS patients undergoing PCI at a regional medical center. All patients with ACS undergoing PCI (n = 728) during a specified time period in 2005 and 2007 were identified. Patients who were switched to the antithrombin bivalirudin were defined as the “switch” group (n = 323) and all others were defined as the “consistent” therapy group (n = 405). Primary endpoints were major adverse cardiac event (MACE) (death, MI or urgent revascularization), major bleeding and net adverse clinical event (NACE) (MACE or major bleeding). Multivariate analysis was performed to determine if switching antithrombotic therapy predicted primary outcomes. Among 728 patients undergoing PCI for ACS, 44% were switched to bivalirudin. Switch patient were more likely to be transfers from outside hospitals, older, female, and diabetic. Angiographic characteristics were similar in the two groups. Switch patients had a similar incidence of MACE (7 vs. 8%, P = 0.72), major bleeding (2 vs. 2%) and NACE (9 vs. 10%, P = 0.51) when compared to those who received consistent therapy. On multivariate analysis, switching did not predict MACE (OR = 0.94, 95% CI = 0.53–1.67, P = 0.84) or NACE (OR = 0.82, 95%CI = 0.48–1.41, P = 0.47). In a regional clinical practice of patients presenting with ACS and undergoing PCI, switching of antithrombin therapy to bivalirudin is a common practice and patient who are switched have similar outcomes compared to patients who receive consistent therapy.
- 1 July 2008
- Vol. 20 (7) , 328-32
Extravascular closure for patients with high-risk femoral anatomy.
Vascular closure devices (VCDs) improve patient comfort and decrease time to ambulation. However, VCD studies have excluded patients with high-risk femoral artery anatomy; we examined the safety and efficacy of clip-based extravascular closure in this high-risk group. We performed a prospective registry enrolling 98 consecutive patients undergoing diagnostic coronary angiography. Inclusion criteria were femoral artery calcification, moderate femoral artery stenosis, or non-femoral arterial sheath insertion. All patients underwent immediate vessel closure with the Starclose device (Abbott Vascular). Patients with severe femoral arterial disease or femoral arterial diameter < or = 4.0 mm were excluded. Hospital outcomes were assessed prospectively and femoral arterial stenosis was determined by quantitative angiography. Inclusion was mainly related to at least one of 3 main high-risk characteristics: moderate femoral arterial stenosis (30%), femoral arterial calcification (24%) or nonfemoral sheath insertion (46%). The average femoral stenosis was 35.3 +/- 5.1% among patients included for a significant femoral disease. There was a 100% procedural and 94% device success: 1 patient required manual compression for greater than or equal to 30 minutes. The average time from sheath removal to hemostasis was 0.76 +/- 1.3 minutes. Despite the higher-risk anatomy, there were no major vascular complications and only one minor vascular complication. The average time to ambulation was 78.1 +/- 47.3 minutes. In this prospective registry, the Starclose VCD was safe and effective for early ambulation of patients despite the presence of high-risk femoral arterial anatomy.
- 1 July 2008
- Vol. 20 (7) , 328-32
Extravascular closure for patients with high-risk femoral anatomy.
Vascular closure devices (VCDs) improve patient comfort and decrease time to ambulation. However, VCD studies have excluded patients with high-risk femoral artery anatomy; we examined the safety and efficacy of clip-based extravascular closure in this high-risk group. We performed a prospective registry enrolling 98 consecutive patients undergoing diagnostic coronary angiography. Inclusion criteria were femoral artery calcification, moderate femoral artery stenosis, or non-femoral arterial sheath insertion. All patients underwent immediate vessel closure with the Starclose device (Abbott Vascular). Patients with severe femoral arterial disease or femoral arterial diameter < or = 4.0 mm were excluded. Hospital outcomes were assessed prospectively and femoral arterial stenosis was determined by quantitative angiography. Inclusion was mainly related to at least one of 3 main high-risk characteristics: moderate femoral arterial stenosis (30%), femoral arterial calcification (24%) or nonfemoral sheath insertion (46%). The average femoral stenosis was 35.3 +/- 5.1% among patients included for a significant femoral disease. There was a 100% procedural and 94% device success: 1 patient required manual compression for greater than or equal to 30 minutes. The average time from sheath removal to hemostasis was 0.76 +/- 1.3 minutes. Despite the higher-risk anatomy, there were no major vascular complications and only one minor vascular complication. The average time to ambulation was 78.1 +/- 47.3 minutes. In this prospective registry, the Starclose VCD was safe and effective for early ambulation of patients despite the presence of high-risk femoral arterial anatomy.